Information Provided By: 
Fly News Breaks for March 28, 2018
DXCM
Mar 28, 2018 | 09:56 EDT
Piper Jaffray analyst JP McKim says he views the label for Dexcom's G6 as stronger than his initial first glance despite the 10 day shut off. The analyst increased his sales numbers for the year and raised his price target for the shares to $80 from $78. The G6 system "offers a plethora of enhancements over the G5 and competitors on the market," McKim tells investors in a research note. He recommends buying the shares with an Overweight rating.
News For DXCM From the Last 2 Days
There are no results for your query DXCM
